Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.
2.

Azacitidine for the treatment of myelodysplastic syndrome.

Cataldo VD, Cortes J, Quintás-Cardama A.

Expert Rev Anticancer Ther. 2009 Jul;9(7):875-84. doi: 10.1586/era.09.61. Review.

PMID:
19589026
3.

The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.

Abou Zahr A, Saad Aldin E, Barbarotta L, Podoltsev N, Zeidan AM.

Expert Rev Anticancer Ther. 2015;15(9):1019-36. doi: 10.1586/14737140.2015.1061936. Review.

PMID:
26292903
4.

The role of azacitidine in the management of myelodysplastic syndromes (MDS).

Götze K, Müller-Thomas C, Peschel C.

Cancer Manag Res. 2009 Oct 9;1:119-30.

5.

Antiproliferative and antitumor effects of azacitidine against the human myelodysplastic syndrome cell line SKM-1.

Kimura S, Kuramoto K, Homan J, Naruoka H, Ego T, Nogawa M, Sugahara S, Naito H.

Anticancer Res. 2012 Mar;32(3):795-8.

PMID:
22399596
6.

Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia.

Keating GM.

Drugs. 2009;69(17):2501-18. doi: 10.2165/11202840-000000000-00000. Review.

PMID:
19911860
7.

Therapy with azanucleosides for myelodysplastic syndromes.

Quintás-Cardama A, Santos FP, Garcia-Manero G.

Nat Rev Clin Oncol. 2010 Aug;7(8):433-44. doi: 10.1038/nrclinonc.2010.87. Review.

PMID:
20551943
8.

Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.

Götze K, Platzbecker U, Giagounidis A, Haase D, Lübbert M, Aul C, Ganser A, Germing U, Hofmann WK.

Ann Hematol. 2010 Sep;89(9):841-50. doi: 10.1007/s00277-010-1015-0. Review.

PMID:
20567826
9.

Advances in myelodysplastic syndrome: nursing implications of azacitidine.

Demakos EP, Linebaugh JA.

Clin J Oncol Nurs. 2005 Aug;9(4):417-23. Review.

PMID:
16117208
10.

5-Azacytidine for the treatment of myelodysplastic syndromes.

Krawczyk J, Keane N, Freeman CL, Swords R, O'Dwyer M, Giles FJ.

Expert Opin Pharmacother. 2013 Jun;14(9):1255-68. doi: 10.1517/14656566.2013.794222. Review.

PMID:
23621771
11.

Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.

Leone G, Voso MT, Teofili L, Lübbert M.

Clin Immunol. 2003 Oct;109(1):89-102. Review.

PMID:
14585280
12.

[Decitabine treatment in myelodysplastic syndromes--results of a compassionate patient program in Israel].

Klepfish A, Silbershatz I, Lugassy G, Shimoni A, Mittelman M.

Harefuah. 2013 Oct;152(10):591-4, 624. Hebrew.

PMID:
24450031
13.

Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes.

Santini V.

Expert Rev Hematol. 2009 Apr;2(2):121-7. doi: 10.1586/ehm.09.6. Review.

PMID:
21083445
16.

Myelodysplastic syndromes: therapy and outlook.

Lyons RM.

Am J Med. 2012 Jul;125(7 Suppl):S18-23. doi: 10.1016/j.amjmed.2012.04.018. Review.

PMID:
22735747
17.

Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations.

Kim YJ, Jang JH, Kwak JY, Lee JH, Kim HJ.

Blood Res. 2013 Jun;48(2):87-98. doi: 10.5045/br.2013.48.2.87.

18.

Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome.

Ritchie EK.

Clin Interv Aging. 2012;7:165-73. doi: 10.2147/CIA.S24659. Review.

19.

Epigenetic therapy in myelodysplastic syndromes.

Musolino C, Sant'antonio E, Penna G, Alonci A, Russo S, Granata A, Allegra A.

Eur J Haematol. 2010 Jun;84(6):463-73. doi: 10.1111/j.1600-0609.2010.01433.x. Review.

PMID:
20192987
20.

Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.

Keating GM.

Drugs. 2012 May 28;72(8):1111-36. doi: 10.2165/11209430-000000000-00000. Review. Erratum in: Drugs. 2012 Jul 30;72(11):1578.

PMID:
22571445

Supplemental Content

Support Center